Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vronib plus Apalolitovolumab for unresectable advanced or metastatic malignant melanoma
ChiCTR2500104409Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in melanoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
vorolanib
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2500104409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104409.